Ketamine and Benzodiazepines: Clinical Interaction Guide

Benzodiazepine use during ketamine treatment for depression is one of the most consequential drug interactions in ketamine practice, because the two medication classes act on opposing brain chemistry. This ketamine and benzodiazepines clinical interaction guide reviews the pharmacological rationale, the clinical evidence, and the management strategies clinicians use when a patient referred for ketamine therapy is already taking a benzodiazepine.

Many patients evaluated for ketamine treatment of treatment-resistant depression (TRD), generalized anxiety disorder, PTSD, or panic disorder are maintained on a benzodiazepine, a class of sedative medications that includes diazepam, lorazepam, clonazepam, and alprazolam. Because benzodiazepines and ketamine influence the same neural circuits in opposite directions, concurrent use raises a practical question: does benzodiazepine co-administration blunt ketamine's antidepressant response, and if so, how should clinicians manage it? Unlike the ketamine-SSRI interaction, where the evidence is largely reassuring, the ketamine-benzodiazepine interaction has implications that call for active management.

Pharmacological Rationale

Opposing mechanisms

Ketamine's antidepressant effect starts with blockade of NMDA receptors, a subtype of glutamate receptor, on GABAergic interneurons. Blocking these receptors disinhibits nearby glutamatergic pyramidal neurons, producing a surge of glutamate release. That surge activates AMPA receptors and triggers downstream signaling, including BDNF release, mTOR pathway activation, and rapid synapse formation, the process thought to underlie ketamine's rapid antidepressant effect according to the National Institute of Mental Health.

Benzodiazepines work through a different receptor system. They act as positive allosteric modulators at GABA-A receptors, strengthening inhibitory GABAergic signaling. This is pharmacologically opposed to the glutamatergic disinhibition ketamine depends on for its antidepressant effect. In simplified terms, ketamine works by releasing a glutamatergic brake that GABAergic interneurons hold on excitatory circuits. Benzodiazepines tighten that same brake.

Preclinical evidence

Animal research supports this opposing-mechanism model. Bhatt and colleagues (2017) reported that diazepam pretreatment blocked ketamine's antidepressant-like effect in the forced swim test in rodents. The same research group found that midazolam given before ketamine reduced ketamine-induced BDNF expression in the prefrontal cortex and hippocampus, regions implicated in the antidepressant response.

Clinical Evidence

Retrospective analyses

Frye and colleagues conducted a post-hoc analysis of patients receiving IV ketamine for treatment-resistant depression and reported significantly lower response rates in patients concurrently taking a benzodiazepine, roughly 25 percent compared with 60 percent in patients not on one. This was among the first clinical data points suggesting a meaningful efficacy reduction.

Ford and colleagues (2023) analyzed a large naturalistic ketamine treatment cohort and found that benzodiazepine co-administration was independently associated with reduced antidepressant response to both IV and intranasal ketamine, even after adjusting for depression severity, anxiety comorbidity, and other confounders.

Prospective and pooled data

A pooled analysis from the Consortium on Research in Ketamine (CORK) examined benzodiazepine status across multiple ketamine clinical trials and found that benzodiazepine use was associated with approximately a 50 percent reduction in the odds of antidepressant response. This association held across different ketamine doses and routes of administration.

These findings come with a caveat. Patients taking benzodiazepines may represent a more treatment-refractory population; their anxiety severity, trauma history, and overall illness burden may independently predict poorer response to any antidepressant treatment. Observational data cannot fully separate the pharmacological interaction from this confounding by illness severity.

Esketamine (Spravato) data

The FDA approved intranasal esketamine (Spravato) in 2019 for treatment-resistant depression, and its clinical trials permitted benzodiazepine co-administration. Subgroup analyses from those trials show mixed results, with some suggesting attenuated response and others finding no significant interaction. Esketamine's prescribing information does not list benzodiazepines as a contraindication, though it notes the potential for additive central nervous system depression.

Clinical Management Strategies

Risk-benefit assessment

Before modifying a patient's benzodiazepine regimen for ketamine therapy, clinicians weigh the potential benefit of improved ketamine response against real risks. Reducing benzodiazepine coverage in a patient with severe anxiety may destabilize their anxiety and compromise the ketamine treatment experience. Patients with seizure risk factors need particular caution with any benzodiazepine change, similar to the caution warranted around other sedative-interacting substances discussed in our ketamine and alcohol interaction guide.

Ketamine dose itself also affects response in patients on concurrent benzodiazepines; see our ketamine dosage guide for dose-response considerations relevant to this population.

Timing considerations

The pharmacokinetics of the specific benzodiazepine matter. Longer-acting agents such as diazepam and clonazepam maintain significant receptor occupancy even when a single dose is held, while shorter-acting agents such as lorazepam and alprazolam clear more quickly. Diazepam's long half-life, 20 to 100 hours including its active metabolite, means holding a single dose provides less pharmacological separation than it would for a shorter-acting agent. Clinicians may time ketamine sessions to coincide with the trough of the benzodiazepine dosing cycle, for example scheduling morning ketamine sessions for patients who take their benzodiazepine at bedtime.

Benzodiazepines for Managing Ketamine Side Effects

Benzodiazepines still have an important role as rescue medications during ketamine sessions. Low-dose midazolam (1-2 mg IV) or lorazepam (0.5-1 mg IV or sublingual) is the standard response to severe emergence reactions, overwhelming dissociation, or acute agitation during a ketamine infusion, part of the broader safety and monitoring protocol for ketamine treatment.

When benzodiazepines are used this way, as a single dose given after the infusion, the impact on antidepressant efficacy is likely minimal, since the glutamatergic cascade has already started. The clinical concern is specifically about scheduled, pre-treatment benzodiazepine dosing that keeps GABAergic activity elevated during the window of ketamine's glutamatergic effect.